Mandolin Raises $40M to Improve Access to Life-Saving Therapies for Diseases like Cancer and Alzheimer's Using AI Agents

曼陀林筹集4000万美元，利用人工智能代理改善癌症和阿尔茨海默病等疾病的救命疗法的可及性。

Mandolin brings AI teammates to healthcare, accelerating patient access and cutting operational cost

曼陀林将人工智能团队成员引入医疗保健领域，加快患者获取速度并降低运营成本。

SAN FRANCISCO, June 25, 2025-- Mandolin, the leading AI automation platform for specialty drug access, announced that it has raised $40 million in funding from Greylock Partners, SignalFire, Maverick, SV Angel, along with Jerry Yang (co-founder of Yahoo!) and Guillermo Rauch (CEO of Vercel). Founded by repeat entrepreneurs Will Yin (CEO) and Rohit Rustagi (COO), Mandolin is used by many of the nation’s largest infusion providers, pharmacies, and health systems..

旧金山，2025年6月25日——Mandolin，领先的特殊药物获取AI自动化平台，宣布已从Greylock Partners、SignalFire、Maverick、SV Angel以及雅虎联合创始人杨致远和Vercel首席执行官吉列尔莫·劳赫处筹集了4000万美元资金。Mandolin由连续创业者Will Yin（首席执行官）和Rohit Rustagi（首席运营官）创立，已被美国许多最大的输液服务提供商、药房和卫生系统采用。

Recent advances in drug development have caused an explosion of specialty therapies addressing rare and chronic conditions like cancers, immune disorders, and Alzheimer’s. Specialty therapies represented $250 billion in drug spend in 2024 and are expected to reach $1.5 trillion in drug spend in eight years.

近年来，药物研发的进展促使了针对癌症、免疫疾病和阿尔茨海默病等罕见和慢性疾病的专科疗法激增。专科疗法在2024年的药品支出为2500亿美元，预计在八年内将达到1.5万亿美元。

They are also 75% of the drugs in the FDA’s approval pipeline..

它们也占FDA审批管道中75%的药物。

Unlike traditional drugs bought at retail pharmacies, these drugs are often administered by healthcare professionals in a clinical setting. They are also processed through an arduous administrative process established by insurance companies, often delaying patients' access to life-changing treatments by weeks..

与传统零售药店购买的药物不同，这些药物通常由医疗专业人员在临床环境中施用。它们还需通过保险公司设立的繁琐行政程序，常常导致患者获得改变生命的治疗延迟数周。

“Insurance companies make the approval process challenging for specialty medications. Infusion providers, pharmacies, and health systems spend an excessive amount of manpower on basic tasks like checking insurance coverage, submitting prior authorizations, or verifying reimbursement amounts, which take weeks of time per prescription and lead to millions in bad debt,” said Will Yin, CEO and co-founder of Mandolin.

“保险公司使特效药物的审批过程变得困难。输液供应商、药房和卫生系统在检查保险覆盖范围、提交事先授权或核实报销金额等基本任务上花费了过多的人力，这些任务每张处方需要数周时间，并导致数百万的坏账，”曼陀林公司的首席执行官兼联合创始人威尔·尹说。

“Leveraging the latest advancements in AI, we saw an opportunity to build autonomous agents that can tackle these workflows for providers in minutes and more reliably.”.

“利用人工智能的最新进展，我们看到了构建自主代理的机会，这些代理可以在几分钟内为供应商解决这些工作流程，并且更加可靠。”

Mandolin’s founders, Will Yin and Rohit Rustagi, have a strong passion and vision for improving our healthcare system using AI. After initially pursuing academic research on conditions like Alzheimer's and cancer that have impacted their families, they saw first-hand the difficulty and delays associated with specialty drug approvals.

曼陀林的创始人尹威尔和罗希特·鲁斯塔吉对利用人工智能改善我们的医疗保健系统充满热情并有着远大的愿景。在最初对影响他们家庭的阿尔茨海默病和癌症等疾病进行学术研究后，他们亲眼目睹了特效药审批的困难和延迟。

Recognizing how broken the healthcare system was for accessing these treatments, combined with the insight that large language models could now reason like the best performing employees, they joined forces to start Mandolin in 2024..

认识到医疗保健系统在获取这些治疗方面有多么破碎，再加上大型语言模型现在能够像表现最好的员工一样进行推理的洞察，他们于2024年联手创立了Mandolin。

Mandolin’s AI platform automates the end-to-end administrative side of infused and injected drug delivery for providers. Mandolin’s AI agents act just like your best employees, completing tasks like reasoning about clinical policies, calling payers, parsing faxes and handwritten notes, and making decisions across entire workflows.

曼陀林的人工智能平台为供应商自动化处理输液和注射药物递送的端到端行政工作。曼陀林的人工智能代理就像你最优秀的员工一样，完成诸如解读临床政策、致电支付方、解析传真和手写笔记，以及在整个工作流程中做出决策等任务。

They integrate into existing electronic health records (EHRs), payer portals, and manufacturer hubs. By centralizing operational logic and real-time decision-making into a single platform, Mandolin dramatically reduces time-to-treatment from weeks to days, lowers back-office costs, improves billing accuracy, and unlocks visibility into drug usage and patient pathways..

它们集成到现有的电子健康记录 (EHR)、支付方门户和制造商中心。通过将操作逻辑和实时决策集中到一个平台上，Mandolin大大缩短了治疗时间，从数周减少到数天，降低了后台成本，提高了账单准确性，并解锁了对药物使用和患者路径的可见性。

Since launching its product in January, the industry has been quick to respond. Mandolin is already working with many of the largest US infusion providers, pharmacies, and health systems, including Vivo Infusion, FlexCare Infusion, OI Infusion, TwelveStone Health Partners, and Amber Specialty Pharmacy.

自今年一月推出其产品以来，行业反应迅速。曼陀林已经与许多美国最大的输液供应商、药房和卫生系统展开合作，包括 Vivo 输液、FlexCare 输液、OI 输液、TwelveStone 健康合作伙伴和琥珀专科药房。

Across customers, Mandolin is deployed in over 700 clinic locations and serves over 250,000 new patients a year..

跨客户群体，Mandolin 已部署在超过 700 个诊所地点，每年为超过 250,000 名新患者提供服务。

'Mandolin has been nothing short of transformational for our business. Tasks that used to take days, now happen in under an hour,” said Cannon Loughry, COO of TwelveStone. “We’ve automated key workflows across billing, patient communication, and insurance verification, driving real gains in terms of better cash flow and the reduction of headcount as we scale.

“曼陀林对我们业务的转变起到了至关重要的作用。过去需要数天才能完成的任务，现在不到一个小时就能完成，”TwelveStone首席运营官坎农·洛里表示。“我们已经自动化了计费、患者沟通和保险验证等关键工作流程，在改善现金流和随着规模扩大减少人员配置方面取得了实际收益。”

Mandolin acts as an AI employee integrated directly into our core systems. We just tell it what needs to get done, and it does the work.”.

曼陀林作为一个人工智能员工直接集成到我们的核心系统中。我们只需告诉它需要做什么，它就会完成工作。

“Will and Rohit saw the opportunity to bring agentic AI into a system drowning in paperwork, delays, and revenue leakage,” said Jerry Chen, partner at Greylock Partners. “Despite being founded a year ago, Mandolin is already proving that AI agents can unlock faster treatment for patients and far better economics for providers.

“威尔和罗希特看到了将代理人工智能引入一个淹没在文书工作、延误和收入流失的系统中的机会，”格雷洛克合伙公司的合伙人杰里·陈说。“尽管曼陀林成立于一年前，但它已经证明了人工智能代理可以为患者解锁更快的治疗，并为供应商带来更好的经济效益。

We at Greylock are thrilled to partner with them on their journey.”.

我们Greylock团队非常高兴能在他们的旅程中与他们合作。

About Mandolin

曼陀林简介

Mandolin is the leading AI automation platform for specialty drug access. The company’s AI agents act just like a best employee, completing tasks like reasoning about clinical policies, calling payers, parsing faxes and handwritten notes, and making decisions across entire workflows. Backed by Greylock, SignalFire, Maverick, and SV Angel, Mandolin works with the largest consolidated infusion providers, specialty and home infusion pharmacies, and health systems in the country.

曼陀林（Mandolin）是专业药物获取领域的领先AI自动化平台。该公司的AI代理表现得像最佳员工，能够完成诸如解读临床政策、致电支付方、解析传真和手写笔记以及在整个工作流程中做出决策等任务。曼陀林得到Greylock、SignalFire、Maverick和SV Angel的支持，与全国最大的综合输液服务提供商、专科及家庭输液药房和卫生系统合作。

For more information, visit: https://www.mandolin.com/.

欲了解更多信息，请访问：https://www.mandolin.com/。

Contact:

联系人：

Media Contact:

媒体联系人:

Mandolin PR — press@mandolin.com

曼陀林公关 — press@mandolin.com